Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind , Controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

NCT04802382 is registered in ClinicalTrials.gov with MGC Pharmaceuticals d.o.o as lead sponsor.

NCT NCT04802382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04802382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind , Controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Lead sponsor
MGC Pharmaceuticals d.o.o
Phase
Phase 3
Overall status
Unknown status
Start date
June 11, 2021
Completion date
April 30, 2023
Enrollment
252 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid19, sars-cov infection